BTIG Reiterates Buy on Monopar Therapeutics, Maintains $104 Price Target
Benzinga Newsdesk 9 months ago
NewsPrice TargetReiterationAnalyst Ratings
BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $104 price target.
BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $104 price target.